NM_032638.5:c.1274C>T
Variant summary
Our verdict is Likely benign. The variant received -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_032638.5(GATA2):c.1274C>T(p.Ser425Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000496 in 1,614,128 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S425P) has been classified as Uncertain significance.
Frequency
Consequence
NM_032638.5 missense
Scores
Clinical Significance
Conservation
Publications
- deafness-lymphedema-leukemia syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
- GATA2 deficiency with susceptibility to MDS/AMLInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- monocytopenia with susceptibility to infectionsInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- acute myeloid leukemiaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- myelodysplastic syndromeInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -6 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| GATA2 | NM_032638.5 | c.1274C>T | p.Ser425Leu | missense_variant | Exon 6 of 6 | ENST00000341105.7 | NP_116027.2 | |
| GATA2 | NM_001145661.2 | c.1274C>T | p.Ser425Leu | missense_variant | Exon 7 of 7 | NP_001139133.1 | ||
| GATA2 | NM_001145662.1 | c.1232C>T | p.Ser411Leu | missense_variant | Exon 6 of 6 | NP_001139134.1 | 
Ensembl
Frequencies
GnomAD3 genomes  0.0000525  AC: 8AN: 152238Hom.:  0  Cov.: 33 show subpopulations 
GnomAD2 exomes  AF:  0.0000318  AC: 8AN: 251472 AF XY:  0.0000147   show subpopulations 
GnomAD4 exome  AF:  0.0000493  AC: 72AN: 1461890Hom.:  0  Cov.: 31 AF XY:  0.0000399  AC XY: 29AN XY: 727244 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000525  AC: 8AN: 152238Hom.:  0  Cov.: 33 AF XY:  0.0000403  AC XY: 3AN XY: 74370 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
not specified    Uncertain:1 
DNA sequence analysis of the GATA2 gene demonstrated a sequence change, c.1274C>T, in exon 6 that results in an amino acid change, p.Ser425Leu. This sequence change has been described in gnomAD with a frequency of 0.0028% in the African sub-population (dbSNP rs146554939). The p.Ser425Leu change affects a moderately conserved amino acid residue located in a domain of the GATA2 protein that is known to be functional. The p.Ser425Leu substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been previously described in patients with GATA2-related disorders. Due to the lack of sufficient evidences, the clinical significance of the p.Ser425Leu change remains unknown at this time. -
GATA2-related disorder    Uncertain:1 
The GATA2 c.1274C>T variant is predicted to result in the amino acid substitution p.Ser425Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-128200031-G-A) and is interpreted as a variant of uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/472441/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Deafness-lymphedema-leukemia syndrome;C3280030:Monocytopenia with susceptibility to infections    Uncertain:1 
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 425 of the GATA2 protein (p.Ser425Leu). This variant is present in population databases (rs146554939, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with GATA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 472441). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GATA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided    Uncertain:1 
In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Hereditary cancer-predisposing syndrome    Uncertain:1 
- -
Acute myeloid leukemia    Uncertain:1 
- -
Inborn genetic diseases    Benign:1 
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at